FindTrial
Sign In

This study will reveal the disappearance HBsAg from blood in patients suffering from chronic Hepatitis B infection and receiving treatment with oral antiviral therapy and whom there in no HBV DNA in his blood sample for at least 1 year while on therapy

Retrospective prospective observational cohort study on incidence of HBsAg loss in chronic hepatitis B patients on oral antiviral medication with sustained undetectable HBV DNA for at least 1 year - HBsAg loss

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/110380
Enrollment
1000
Registered
2026-05-11
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K00-K95- Diseases of the digestive system

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Chronic Hepatitis B patients on oral antiviral therapy with HBV DNA not detectable for at least 1 year Willing to give consent

Exclusion criteria

Exclusion criteria: HCV/HIV/HDV coinfection Decompensated cirrhosis Hepatocellular Carcinoma Prior interferon therapy Poor compliance

Design outcomes

Primary

MeasureTime frame
To calculate the incidence of HBsAg loss after 1 yearTimepoint: To calculate the incidence of HBsAg loss after 1 year from the date of enrollment—

Secondary

MeasureTime frame
Factors affecting the HBsAg lossTimepoint: 1 year—

Countries

India

Contacts

Public ContactDR MOINUDDIN AHAMMED

IPGMER SSKMH KOLKATA

skmahiuddinahammed@gmail.com9051157404

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026